Back

Valvular heart disease in Cancer patiEntS - prevAlence, Relevance, and therapeutic management - preliminary results from the CESAR study

29 August 2025 (12:15 - 13:00)
Organised by: Logo
Congress Presentation Part of: Special populations in cardio-oncology Diagnosis and Management of Cardiovascular Disease in Patients with Cancer ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Laurenz Hauptmann

Medical University of Vienna, Vienna (Austria)

8 More presentations in this session

Presentation thumbnail
Dysfunctional high-density lipoproteins in breast cancer patients and tumor-bearing mice treated with chemotherapy
Professor S. Lecour (Cape Town, ZA)
Abstract Slides Video
Presentation thumbnail
Low cardiovascular event rates in patients treated with CAR T-cells: real-world outcomes from two independent cohorts
Mr J. Voran (Kiel, DE)
Abstract Slides Video
Presentation thumbnail
Novel biomarker-based machine learning model in personalized cardiotoxicity prediction.
Ms I. Liu (Austin, US)
Abstract Slides Video
Presentation thumbnail
The incidence and risk factors for early onset atrial fibrillation in allogeneic and autologous hematopoietic stem cell transplant patients
Ms L. Cai (Duarte, US)
Abstract Slides Video
Presentation thumbnail
Clinical and echocardiographic characteristics of neuroendocrine tumours and carcinoid heart disease: insights from a contemporary canadian cohort study
Mr J. Yoon (Vancouver, CA)
Abstract Slides Video

Access the full session

Session thumbnail
Special populations in cardio-oncology

The Event

Event poster

ESC Congress 2025

29 August 2025 12:15 CET
You may be interested in
thumbnail
Congress Presentation
Influence of tumour history in valve damage in patients undergoing mitral or aortic valve replacement
thumbnail
Congress Presentation
Clinical outcomes of TAVI in patients with active cancer: a bridge to success?
thumbnail
Congress Session
The EHJ’s year in adult congenital heart disease, cardio-oncology, and valvular heart disease

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources